Skip to main content
. 2020 Mar 30;69(7):1363–1373. doi: 10.1007/s00262-020-02551-6

Table 2.

Overall distribution of LAG3, CD8 and TP53 mutations depending on clinical/tumor criteria; percentages per variable are displayed in parentheses

LAG3 CD8+ inflammation TP53
Negative Positive p Not inflamed Inflamed p Not mutated Mutated p
Age group
 < 65 years 52 (71.2) 15 (51.7) 52 (66.7) 17 (63) 49 (71) 16 (51.6)
 ≥ 65 years 21 (28.8) 14 (48.3) 26 (33.3) 10 (37) 20 (29) 15 (48.4)
Gender
 m 35 (47.3) 12 (41.4) 35 (44.3) 13 (48.1) 30 (42.9) 16 (51.6)
 w 39 (52.7) 17 (58.6) 44 (55.7) 14 (51.9) 40 (57.1) 15 (48.4)
Alcohol
 No 49 (80.3) 20 (83.3) 55 (83.3) 16 (76.2) 49 (84.5) 18 (72)
 Yes 10 (16.4) 4 (16.7) 10 (15.2) 4 (19) 9 (15.5) 5 (20)
 Abuse 2 (3.3) 0 (0) 1 (1.5) 1 (4.8) 0 2 (8)
Nicotine
 No 50 (80.6) 18 (78.3) 55 (83.3) 15 (71.4) 48 (82.8) 18 (72)
 Yes 12 (19.4) 5 (21.7) 11 (16.7) 6 (28.6) 10 (17.2) 7 (28)
Therapy
 Surgery 31 (46.3) 8 (30.8) 34 (47.2) 7 (30.4) 33 (52.4) 6 (21.4)
 +RTX/CTX 36 (53.7) 18 (69.2) 38 (52.8) 16 (69.6) 30 (47.6) 22 (78.6)
T
 T1 21 (30) 2 (7.1) 19 (25.7) 5 (18.5) 23 (33.8) 0 0.02
 T2 14 (20) 11 (39.3) 19 (25.7) 6 (22.2) 15 (22.1) 8 (28.6)
 T3 15 (21.4) 4 (14.3) 16 (21.6) 5 (18.5) 13 (19.1) 7 (25)
T4a 14 (20) 8 (28.6) 12 (16.2) 10 (37) 12 (17.6) 9 (32.1)
 T4b 6 (8.6) 3 (10.7) 8 (10.8) 1 (3.7) 5 (7.4) 4 (14.3)
N
 N0 47 (69.1) 11 (39.3) 0.001 50 (67.6) 11 (44) 0.008 48 (71.6) 10 (35.7) <0.001
 N1 8 (11.8) 1 (3.6) 8 (10.8) 1 (4) 7 (10.4) 2 (7.1)
 N2a 0 2 (7.1) 0 2 (8) 2 (3) 0
 N3 13 (19.1) 14 (50) 16 (21.6) 11 (44) 10 (14.9) 16 (57.1)
UICC stadium
 I 17 (25.4) 2 (7.4) 0.009 16 (22.2) 4 (16) 19 (28.4) 0 <0.001
 II 13 (19.4) 7 (25.9) 15 (20.8) 5 (20) 14 (20.9) 5 (19.2)
 III 14 (20.9) 1 (3.7) 16 (22.2) 1 (4) 13 (19.4) 3 (11.5)
 IVa 7 (10.4) 2 (7.4) 6 (8.3) 3 (12) 8 (11.9) 1 (3.8)
 IVb 15 (22.4) 12 (44.4) 18 (25) 9 (36) 10 (14.9) 16 (61.5)
 IVc 1 (1.5) 3 (11.1) 1 (1.4) 3 (12) 3 (4.5) 1 (3.8)

RTX: radiotherapy, CTX: chemotherapy